| Author (year) | Oxygen concentration | Dose (per animal), time (hours), method | Time of assessment | Outcomes |
| van Haaften (2009) | 95% | (1) BMSC, P4, IT (2) BMSC , P14, IT | P21, P4 | Alveolarization, lung angiogenesis, PH, exercise capacity, survival rate | Aslam (2009) | 75% | (1) cells P4, IV (2) BMSC-CM 50 μl, P4, IV | P5/P14 | Alveolarization, lung inflammation, PH, vascular injury | Chang (2009) | 95% | (1) cells, P5, IT (2) cells, P5, IP | P14 | Weight, survival, alveolarization, apoptosis, lung inflammation, and fibrosis | Chang (2011) | 95% | (1) cells (2) cells (3) cells, P5, IT | P14 | Weight, survival, alveolarization, apoptosis, lung inflammation, MPO activity, lung fibrosis, oxidative stress | Chang (2013) | 90% | cells P3/P10/P3+P10, IT | P1, P3, P5, P7, P10 P14, P21 | Weight, survival, alveolarization, apoptosis, lung inflammation, fibrosis, oxidative stress | Zhang (2012) | 95% | cells, P10, IV | P13, P17, P24 | Weight gain, lung inflammation, alveolarization, tissue cytokine | Waszak (2012) | 95% | 1 ml/kg, P0-P20, IP | P21 | Alveolarization, pH, PA remodeling | Sutsko (2013) | 90% | (1) cells, P9, IT (2) 0.05 ml MSC-CM, IT | P16, P30, P100 | Alveolarization, lung angiogenesis and inflammation, PH | Pierro (2013) | 95% | (1) MSCs, P4, IT (2) MSCs, P14, IT (3) 7 μl/g CdM, P4-P21, IP (4) 7 μl/g CdM, P14-P28, IP | P22, P35, P6 months | Alveolarization, PA remodeling, PH, lung angiogenesis, function, exercise capacity | Ahn (2013) | 90% | cells, P5, IT | P70 | Alveolarization, lung inflammation, angiogenesis, safety, weight, survival rate | Sung (2015) | 90% | (1) cells P5, IT (2) cells P5, IV | P14 | Alveolarization, lung inflammation Cell death, fibrosis | Ahn (2015) | 90% | (1) hUB-MSC cells (2) AT MSC cells (3) hUB-MNC cells; P5, IT | P7, P14 | Alveolarization, lung inflammation, angiogenesis | Gulasi (2016) | 85-95% | (1) cells (2) Culture medium 25 μl (3) Remaining medium 25 μl, P11, IT | P10, P60 | Lung/body weight, alveolarization, lung fibrosis, inflammation |
|
|